Member Info for ThinShins

Tommy where have you seen Janssen talk about this trial?

Only comms Iv seen are from Synairgen and UoS.

DocD, the New Years communication from RM which I'm sure you have already read is the only recent thing we have to get an idea as to what the company's "absolute focus" will be going forward. To me its quite clear they are looking to capitalise on the broad-spectrum antiviral properties of SNG001 against RVIs, how this will be achieved is yet to be seen.

"As it stands today, there are no broad-spectrum antivirals approved for use in patients with severe viral lung infections who are at increased risk of progressing to severe disease or death, and this is in the context of more than 3 million people a year being hospitalised due to these infections in the US alone. It is then perhaps not surprising that this also means there is no precedent for a broad-spectrum antiviral clinical development programme. Designing and determining a clinical pathway for this approach is complex, as there are multiple viruses being targeted for different high-risk patient groups.

This is our absolute focus. The Synairgen team, and our partners and advisors, have been working relentlessly to identify the optimal clinical development programme to confirm the signals we have seen, and investigate SNG001 against this wide spectrum of respiratory viruses."

I am unsure as to how recent the link has been updated but Google indicates 7 days ago.

“I specialise in capital markets and M&A, with a focus on the natural resources and healthcare sectors.”

“Advising Synairgen on several secondary placings.”

https://www.fladgate.com/our-team/nigel-gordon

Interesting to me that we are on the radar of UK’s Department of International Trade, their Twitter bio reads: “DIT helps businesses export, drives inward and outward investment, negotiates market access and trade deals and champions free trade”

We are delighted to have been selected as a UK Life Sciences #Innovator 2023 by @tradegovuk, as part of the @Arab_Health Exhibition!

More details can be found here: eu.eventscloud.com/website/9999/

#LSI2023 #ArabHealth2023 #UKInnovation

https://twitter.com/synairgenplc/status/1620393612226998272

https://youtu.be/o1GkB_RZzrA

Full podcast ^

https://twitter.com/synairgenplc/status/1597579747210526720

Host Directed, our new series exploring the need for new types of antivirals to treat severe respiratory infections, @ProfWilko & Vicki Tear discuss how antiviral agents work and potential benefits of broad-spectrum antivirals

Synairgen is mentioned in the section Conflict of interest: "TC has received consultancy fees from Biofire diagnostics LLC, BioMerieux, Synairgen research Ltd, Randox laboratories Ltd and Cidara therapeutics.".

TC I assume is Tristan W. Clark.

From the same paragraph:

"TC has been a member of advisory boards for Roche and Janssen and has received reimbursement for these. TC is member of two independent data monitoring committees for trials sponsored by Roche. TC has previously acted as the UK chief investigator for trials sponsored by Janssen. TC is currently a member of the NHSE COVID-19 Testing Technologies Oversight Group and the NHSE COVID-19 Technologies Validation Group. JS is a founding director, CEO, employee, and shareholder in TopMD Precision Medicine Ltd. "

DocD, you say Synairgen is not in the business of " comprehending how and why some people's lungs are unable to defend themselves"

Ofcourse they are, how would you expect them to produce a treatment?

Not sure if you saw but user cl2201 pointed out earlier the striking similarity in thr statement from the job post and https://www.synairgen.com/about "Understanding how and why some people’s lungs are unable to defend themselves has been at the heart of the Synairgen story for nearly 50 years."

looks like astrazeneca also co-funding this trial:

"This trial is funded by Janssen Pharmaceuticals and AstraZeneca, with support in kind from Synairgen Ltd."

Few mentions of STRIVE platform trial, can someone please provide a link or explanation what this trial is?

I’ve had google and I can’t pinpoint exactly which trial is being referred to. Thanks and apologies if I missed a explanation or l link that’s already been posted.

Agree with Patagucci, I don't expect anything crazy. Are AGMs ever even used to break any type of substantial news?

https://youtu.be/Kh0X4faAVyE

Docdaneeka, I understand what you are saying and I usually would not respond to most of the noise however reading Anybe4's post I just thought it was unfair that the company we are invested in and the people running the company were being described with terms such as "no urgency" and "sluggish" so I thought it warranted a response in defence of those who are moving mountains to save lives globally and earn us some cash in the process. Also bit of a quiet Friday night for me.

ATB to you Doc

Andybe4, the difference between Pfizer and Synairgen trials is that Pfizer's trial was under a rolling submission, data was being fed to regulators as it came. The whole world and every governmental health agency had hawk eyes on Pfizer and AstraZeneca due to the global demand and urgency for vaccines.

"I am beginning to see the trend by Synairgen that there is no urgency in deploying this drug at all." quite a wild statement.

Do you think the team are sat around eating KP peanuts and playing twister in the offices with RM walking in "so then, anyone fancy trying to get our drug approved that we been developing for over 15 years?" they all laugh "nah it can wait another couple more months" they go on to drag RM into a fresh twister round.

Or do you think the team are working endlessly and tirelessly with all parties involved to get the P3 readout and EUA submission bang on the money as they really could not afford to have this go tits up at this stage.

As you can see from sleuthing and research from many posters across different platforms there is so much going on behind the scenes. Prime example yesterday nobody had a clue about Synairgen being first client for Ray Jordan's consultancy firm Putnam Insights. This must have been in the works for months, who knows what other nuggets are yet to come. PS thanks Brand for that find.

If you have researched the BoDs you should be aware that they are all highly credible and add great value to the company with their vast experience from being in senior positions in big pharma companies, describing the efforts of the company with terms such as "sluggish" is imo unfair.

AIMO best of luck all, have a great weekend. Not much longer now.

FWIW I just signed up to ADVFN to have a gander and I can see that the user who started the thread Northern66 has updated at 15:37 with the following:

"Thanks for the feedback. He is a very reliable source when it comes to biotechs and he is heavily invested here.
I did call the harbour hotel, they said they have had many calls and all they can say is that the room is booked. No names given."

https://twitter.com/ACTGNetwork/status/1493696902243758082

https://www.nationalgeographic.com/science/article/worlds-brightest-x-rays-reveal-covid-19-damage-to-the-body

https://www.cell.com/trends/immunology/current#fullCover

In addition to other themes, this issue comprises reviews and opinion articles on human immune responses against infections (such as SARS-CoV-2), including aspects of evolution, natural resistance, and vaccination.

As an example, depicted here, are interferons and SARS-CoV-2 caught in an epic battle to ‘knock out’ each other. The SARS-CoV-2 character appears on a background of SARS-CoV-2-infected cells stained for the nucleocapsid protein (red), and the interferon character appears on a background of healthy human airway cells in which the nuclei are stained in blue (see also Trends in Immunology 2021;42(12):1069–1072). Image credit: Arinjay Banerjee, Kaushal Baid, and Ayantika Roy. Cover design: Catarina Sacristán.

Courtesy of @1985muenchen on Twitter.

Planning Committee Member: Richard Hennings - CCO at Synairgen Research ltd

Hosted by the American Thoracic Society, the 2022 Respiratory Innovation Summit will unite the innovators, investors, clinicians and advocacy groups who are leading the charge to create powerful new treatments for deadly and crippling diseases of the lungs and airways.

Event Date: May 13-18
Application Deadline: Feb. 25, 2022

https://conference.thoracic.org/program/ris/index.php